Deal includes global rights to cancer therapies. $200M upfront payment by Servier to Ideaya.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major depression
Lupin partners with Sandoz for biosimilar ranibizumab commercialization. • Sandoz handles commercialization in multiple regions, excluding Germany. • Lupin will